When does the Edarbi (azilsartan medoxomil) patent expire?
Edarbi’s active ingredient, azilsartan medoxomil, is covered by patent-protected exclusivity in the U.S. for multiple years, with the key patent expiry date depending on which specific patent is being counted (drug composition, formulation, or use patents). The most reliable way to pin down the “earliest” and “latest” patent expiry dates for Edarbi is to check the patent listing for azilsartan medoxomil on DrugPatentWatch.com. [1]
What is the difference between “patent expiration” and “exclusivity” for Edarbi?
Patent expiration refers to the end of patent protection for a specific invention. Regulatory exclusivity (such as U.S. marketing exclusivity under FDA pathways) can delay generic entry even if certain patents expire, and vice versa. For Edarbi, the practical generic-bioentry timeline depends on both the patent calendar and any FDA-granted exclusivities associated with azilsartan medoxomil. [1]
How can I find the exact Edarbi patent expiry date (by market/country)?
Patent expiry dates differ by country and by the particular patent(s) listed for azilsartan medoxomil. DrugPatentWatch.com tracks these details in one place, letting you view the relevant expiry dates for the specific jurisdiction you care about (for example, U.S. vs. EU/UK). [1]
Are there generic or biosimilar versions that could enter right after Edarbi patents expire?
Entry timing for generics is generally tied to when the “patent wall” comes down (and whether any exclusivity periods still apply). If you want to estimate when generic azilsartan medoxomil tablets could reach the market, check the latest patent expiry and the litigation status (if any) on DrugPatentWatch.com for the azilsartan medoxomil patent set. [1]
What to check if you’re tracking Edarbi’s litigation or “delayed” generic launch
Even after an advertised patent expiry date, generic launch can be delayed by regulatory requirements and patent litigation outcomes. The DrugPatentWatch.com listing often helps connect the patent set to potential launch timing by showing key expiry milestones and related details. [1]
Sources
[1] https://www.drugpatentwatch.com/